Literature DB >> 3462245

Endogenous inhibitor of protein kinase C: association with human peripheral blood neutrophils but not with specific granule-deficient neutrophils or cytoplasts.

K J Balazovich, J E Smolen, L A Boxer.   

Abstract

A Ca2+-activated and phospholipid-dependent protein kinase (PKC) has been described in several cell systems, including the human neutrophil. We found that less than 30 pmol 32P/10 min/10(6) cell equivalents of phorbol ester- or 1-oleoyl-2-acetylglycerol-stimulated PKC activity was obtained when neutrophil homogenates were used as an enzyme source. However, detergent-soluble and detergent-insoluble fractions prepared from the same homogenates, respectively, catalyzed 578 +/- 50 and 136 +/- 40 pmol 32P/10 min/10(6) cell equivalents. Recombining detergent-soluble and detergent-insoluble fractions resulted in the complete loss of activity. We therefore explored the possibility of an endogenous inhibitor of PKC in neutrophils. Homogenates from neutrophil cytoplasts, which lack the nuclei and intracellular granules of whole neutrophils, yielded 813 +/- 28 pmol 32P/10 min/10(6) cell equivalents. In addition, total neutrophil homogenates from a patient with a specific granule deficiency yielded high activities, namely 424 +/- 48 pmol 32P/10 min/10(6) cell equivalents. Specific granule-deficient neutrophils possessed translocated and activated PKC, and phosphoprotein patterns from these cells resembled those from activated normal neutrophils. Our results suggested the existence of an inhibitor of previously active PKC. That this inhibitor is primarily associated with neutrophil-specific granule membranes was suggested by our finding of high PKC activity associated with cell preparations or combinations of cell fractions that were free of specific granules, but not necessarily of other cellular organelles. Preliminary characterization of the endogenous inhibitor indicated that it was protease- and heat-sensitive, and did not exhibit either protease or phosphatase activity. We speculate that the inhibitor may play a physiologic role in regulating the activity of its target enzyme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462245

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Functional inhibition of protein kinase C-mediated effects in myocardial tissue is due to the phosphatase 2A.

Authors:  S Braconi; D J Church; M B Vallotton; U Lang
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  Immunoregulatory effects of sizofiran (SPG) on lymphocytes and polymorphonuclear leukocytes.

Authors:  K Yoneda; E Ueta; T Yamamoto; T Osaki
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

3.  Purification of PKC-I, an endogenous protein kinase C inhibitor, and types II and III protein kinase C isoenzymes from human neutrophils.

Authors:  K J Balazovich; E L McEwen; M L Lutzke; L A Boxer; T White
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

4.  Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Stimulation of protein kinase C redistribution and inhibition of leukotriene B4-induced inositol 1,4,5-trisphosphate generation in human neutrophils by lipoxin A4.

Authors:  K O Chung-a-on; O Soyombo; B W Spur; T H Lee
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.

Authors:  K Yoneda; T Yamamoto; E Ueta; T Osaki
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.